Mutations in HIV-1 gag and pol compensate for the loss of viral fitness caused by a highly mutated protease.

Abstract excerpt

During the last few decades, the treatment of HIV-infected patients by highly active antiretroviral therapy, including protease inhibitors (PIs), has become standard. Here, we present results of analysis of a patient-derived, multiresistant HIV-1 CRF02_AG recombinant strain with a highly mutated protease (PR) coding sequence, where up to 19 coding mutations have accumulated in the PR. The results of biochemical...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antiretroviral Therapy, Highly Active
• Share to gag Gene Products, Human Immunodeficiency Virus